A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

NCT05104463 | Completed Phase 2 Results FDA Drug

• 1 other identifier: CST2032/CST107-CLIN-015
• Study Type: interventional
• Target: 64
• Locations: 2 countries
• Sites: 15

Brief Summary

This is a Phase 2a, randomized, placebo-controlled, double-blind, crossover study to evaluate the effects CST-2032 administered with CST-107 on cognition in participants with Mild Cognitive Impairment (MCI) or mild dementia.

Conditions

Mild Cognitive Impairment; Dementia

Outcome Measures

Primary Outcomes (3)

• Treatment-emergent Adverse Events

  The number of participants experiencing treatment-emergent adverse events after receiving 3mg CST-2032 co-administered with 3mg CST-107 compared to placebo

  Change from Baseline after 14 days of treatment

• Vital Signs

  Change from Baseline in supine blood pressure (diastolic blood pressure and systolic blood pressure) after CST-2032 co-administered with CST-107 compared to placebo

  Change from Baseline after 14 days of treatment respectively (4 hours post dose)

• Electrocardiograms (ECGs)

  Change from Baseline in QTc interval using the Fredericia (QTcF) corrections after treatment with CST-2032 co-administered with CST107 compared to placebo

  Change from Baseline after 14 days of treatment respectively (4 hour post-dose)

Secondary Outcomes (8)

• Change From Baseline in DSST Score

  Change from Baseline after 7 and 14 days of treatment respectively.

• Change From Baseline in DSST Total Incorrect

  Change from Baseline after 7 and 14 days of treatment respectively.

• Change From Baseline in CANTAB Stop Signal Reaction Time

  Change from Baseline after 7 and 14 days of treatment respectively.

• Change From Baseline in CANTAB 5-Choice Reaction Time

  Change from Baseline after 7 and 14 days of treatment respectively.

• Change From Baseline in CANTAB Paired Associates Learning Tool - Total Adjusted Errors

  Change from Baseline after 7 and 14 days of treatment respectively.

Study Arms (2)

CST-2032 (3mg)/CST-107 (3mg) to Placebo

EXPERIMENTAL

Participants will receive daily doses of CST-2032 (3mg) co-administered with CST-107 (3mg) for 14 days, followed by a washout period of no drug for 7 days, followed by matching placebo for CST-2032 and matching placebo for CST-107 for 14 days.

Drug: CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107

Placebo to CST-2032 (3mg)/CST-107 (3mg)

EXPERIMENTAL

Participants will receive matching placebo for CST-2032 and matching placebo for CST-107 for 14 days followed by a washout period of no drug for 7 days, followed by daily doses of CST-2032 (3mg) co-administered with CST-107 (3mg) for 14 days.

Drug: CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107

Interventions

CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107 DRUG

CST-2032 and matching placebo white tablets, CST-107 and matching placebo yellow tablets

CST-2032 (3mg)/CST-107 (3mg) to Placebo; Placebo to CST-2032 (3mg)/CST-107 (3mg)

Eligibility Criteria

• Age: 50 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female participants ≥ 50 and ≤ 85 years of age at time of informed consent.
• Diagnosis of mild cognitive impairment OR mild dementia due to either: Parkinson's disease associated with REM sleep behavior disorder (RBD+PD) and positive response to the RBD Single-Question Screen (RBD1Q) and without hallucinations; OR Alzheimer's Disease (AD).
• For participants taking medications: stable dose and regimen for at least 30 days (90 days for anti-psychotic medications) prior to Day -1 and the dose must remain unchanged through the End of Study Visit unless required for management of adverse events (AEs).
• Cognitive decline not primarily caused by vascular, traumatic, or medical problems (alternative causes of cognitive decline are ruled out).
• Adequate visual and auditory abilities and motor skills to perform all aspects of the cognitive and functional assessments.
• Has a spouse or caregiver who can accompany the subject at specified study visits (if required based on cognitive function).
• Montreal Cognitive Assessment (MoCA) score ≥ 14 and ≤ 26.
• Unless confirmed to be azoospermic (vasectomized or secondary to medical cause), males must agree to use a male condom from Day -1 until the End of Study visit when having penile-vaginal intercourse with a woman of childbearing potential who is not currently pregnant. Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a condom during each episode of penile-vaginal penetration until after the End of Study Visit.
• Females of childbearing potential (i.e., not postmenopausal or surgically sterile) who have a male partner must have a negative serum pregnancy test result and must agree to one of the following from start of Screening through 30 days after the last study medication administration: use a highly effective method of birth control; or monogamous relationship with a male partner of confirmed sterility; or practice complete abstinence.
• Females of non-childbearing potential may be enrolled if it is documented that they are postmenopausal.
• Body weight greater or equal to 50 kg and body mass index (BMI) between 18 and 35 kg/m\^2, inclusive at Screening.
• Stable medical conditions for 30 days prior to Screening visit (e.g., controlled hypertension, dyslipidemia).
• Willing to follow the protocol requirements and comply with protocol restrictions.
• Capable of providing informed consent and complying with study procedures.
• Able to speak, understand and read English.

You may not qualify if:

• Participants with poorly controlled hypertension despite lifestyle modifications and/or pharmacotherapy.
• Participants with pulmonary disease, including asthma, or evidence of clinically significant moderate or severe pulmonary symptoms.
• Clinical signs indicating syndromes such as corticobasal degeneration, supranuclear gaze palsy, multiple system atrophy, chronic traumatic encephalopathy, signs of frontotemporal dementia, history of stroke, head injury or encephalitis, cerebellar signs, early severe autonomic involvement, or Babinski sign.
• Current evidence of epilepsy, focal brain lesion, head injury with loss of consciousness or meeting DSM-V diagnostic criteria for psychotic disorders, such as schizophrenia or bipolar disorder, or have unstable concomitant psychiatric symptomatology (participants with psychotic disorders may be enrolled if their condition is effectively managed, i.e., must be receiving stable doses of anti-psychotic medications(s) 90 days prior to randomization and must remain on that dose throughout both treatment periods.)
• Evidence of any significant clinical disorder or laboratory finding (e.g., potassium levels below normal range) that renders the participant unsuitable for receiving an investigational drug including clinically significant or unstable hematologic, moderate and severe impairment of hepatic function (as defined by the National Cancer Institute Organ Dysfunction Working Group), cardiovascular, pulmonary, gastrointestinal, endocrine (including thyrotoxicosis, excluding managed hypo and hyperthyroidism), immunologic, dermatologic, neurologic, musculoskeletal, metabolic, renal, or other systemic disease or laboratory abnormality.
• Participants with a history of malignant disease within 5 years, including solid tumors and hematologic malignancies (exceptions: \[a\] basal cell and squamous cell carcinomas of the skin that have been completely excised and are considered cured; \[b\] low-grade adenocarcinoma of the prostate, which are slow growing, and are unlikely to progress or metastasize during the clinical trial).
• Any clinically significant medical condition or disease as determined by medical history, physical examination 12-lead electrocardiogram (ECG) and clinical laboratory assessments conducted that, in the view of the Principal Investigator, will interfere with participation in the study or interpretation of results.
• Clinically significant abnormalities of 12-lead ECG (as determined by a central reader), including QTcF \> 440 ms, for males and females, and/or HR \< 50 beats per minute, or evidence of bundle branch blocks, as indicated on the Mean ECG Analysis Report during the screening Period.
• A calculated creatinine clearance of ≤60 mL/min according to the Cockcroft-Gault equation.
• Current use of any prohibited prescription medication, over-the-counter medication, or herbal supplements including green tea products during Screening or throughout study, unless approved by both the Investigator and the Sponsor Medical Monitor.
• Prior and/or concurrent treatment with any investigational drug ≤90 days prior to dosing (Day 1), or ≤5 half-lives of the drug (whichever is longer), or current enrollment in any other study treatment or disease study, except for observational studies.
• Prior and/or concurrent treatment with any beta-AR agonists or beta-AR blockers (includes oral meds, IV or inhaled) or any meds that impact adrenergic signaling within the last month prior to Screening. Participants may be on stable doses of serotonin-noradrenaline reuptake inhibitors (SNRIs), or tricyclic antidepressants (TCAs), or any treatment for ADHD including noradrenaline reuptake inhibitors (NRIs), or amphetamines within the last month prior to Screening.
• A history of heart failure, sinus bradycardia, second- or third-degree heart block, hypokalemia, attack of unconsciousness possibly associated with torsades de points or family history of Long QT Syndrome.
• Known or suspected alcohol or substance abuse within the past 12 months and/or positive test for alcohol or drugs of abuse at Screening or Day -1.
• Suicidal ideation with actual intent or plan ("Yes" answer on the C-SSRS ideation items 4 or 5) within 3 months prior to study Screening.

Sponsors & Collaborators

• CuraSen Therapeutics, Inc.: lead

Study Sites (15)

CuraSen Investigational Site

Scottsdale, Arizona, 85258, United States

Location

CuraSen Investigational Site

Lafayette, California, 94549, United States

Location

CuraSen Investigational Site

Boca Raton, Florida, 33486, United States

Location

CuraSen Investigational Site

Bradenton, Florida, 34205, United States

Location

CuraSen Investigational Site

Lady Lake, Florida, 32159, United States

Location

CuraSen Investigational Site

Miami, Florida, 33176, United States

Location

CuraSen Investigational Site

New Port Richey, Florida, 34652, United States

Location

CuraSen Investigational Site

Winter Park, Florida, 32792, United States

Location

CuraSen Investigational Site

New York, New York, 10003, United States

Location

CuraSen Investigational Site

Cincinnati, Ohio, 45242, United States

Location

CuraSen Investigational Site

Houston, Texas, 77074, United States

Location

CuraSen Investigational Site

Round Rock, Texas, 78681, United States

Location

CuraSen Investigational Site

Stafford, Texas, 77477, United States

Location

CuraSen Investigational Site

Salt Lake City, Utah, 84102, United States

Location

CuraSen Investigational Site

Christchurch, 8011, New Zealand

Location

MeSH Terms

Conditions

Cognitive Dysfunction; Dementia

Condition Hierarchy (Ancestors)

Cognition Disorders; Neurocognitive Disorders; Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Results Point of Contact

• Title: Clinical Trial Information Desk
• Organization: CuraSen Therapeutics, Inc

clinicaltrials@curasen.com

+1 650 475 2842

Study Officials

• Chief Medical Officer

  CuraSen Therapeutics, Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 20, 2021
• First Posted: November 3, 2021
• Study Start: April 11, 2022
• Primary Completion: December 20, 2023
• Study Completion: February 1, 2024
• Last Updated: January 23, 2025
• Results First Posted: January 23, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will not share

Locations

NZ (1); US (14)